Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion Bristol-Myers Squibb Company with its wholly-owned subsidiary Celgene Corporation announced the commencement of 20 separate offers to purchase for cash notes issued by the Offerors listed in the tables below for an aggregate purchase price of up to $4.0 billion. 2023 Pool Offers to purchase for cash up to $950,000,000 aggregate purchase price for the securities listed in the priority order below. 2024 Pool Offers to … Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol Myers Squibb”), with its wholly-owned subsidiary Celgene Corporation (“Celgene”) (collectively, the “Offerors”), announced the commencement of 20 separate offers to purchase for cash notes issued by the Offerors listed in the tables below (collectively, the “Notes”) for an aggregate purchase price of up to $4.0 billion.